Patient |
Therapy |
B‑Raf mutation |
Cancer regression index (%) |
A |
IRIS + Panitumumab |
1326V |
115 |
B |
IRIS + Panitumumab |
- |
34.3 |
C |
IRIS + Panitumumab |
- |
18.5 |
D |
IRIS + Panitumumab |
- |
17.8 |
E |
IRIS + Panitumumab |
- |
11.3 |
F |
IRIS + Panitumumab |
D22N |
5 |
G |
FOLFIRI + Cetuximab |
- |
5.1 |
H |
IRIS + Panitumumab CPT - 11 + Cetuximab |
- |
0.1 |
I |
IRIS + Panitumumab |
- |
-7.4 |
J |
CPT - 11 + Cetuximab |
- |
-11.6 |
K |
mFOLFOX6 + Panitumumab |
V600E |
-11.5 |
L |
IRIS + Panitumumab |
- |
-12.5 |
M |
mFOLFOX6 + Cetuximab |
- |
-15.9 |
N |
IRIS + Panitumumab |
- |
-19.1 |
O |
IRIS + Panitumumab mFOLFOX6 + Cetuximab sLV5FU2 + Cetuximab |
N581Y |
-22.4 |
P |
IRIS + Panitumumab |
- |
-27 |
Q |
FOLFIRI + Cetuximab |
- |
-26.6 |
R |
CPT - 11 + Cetuximab |
- |
-32.8 |
S |
mFOLFOX6 + Panitumumab |
- |
-33.8 |
T |
IRIS + Panitumumab |
- |
-33.7 |
U |
CPT - 11 + Panitumumab |
V600E |
-35.7 |
V |
CPT - 11 + Panitumumab |
- |
-36.8 |
W |
IRIS + Panitumumab |
- |
-52.8 |
X |
mFOLFOX6 + Cetuximab |
- |
-55 |
Y |
mFOLFOX6 + Panitumumab |
- |
-72.3 |
Z |
IRIS + Panitumumab |
- |
-72.7 |
B‑Raf mutation |
Number of patients |
Average cancer regression index (%) |
Standard deviation |
1326V |
1 |
115 |
- |
D22N V600E N581Y |
4 |
-16.3 |
17.3 |
No mutation |
22 |
-19 |
28.9 |